New cystic fibrosis triple from Vertex backed for NHS use Vertex has won NICE's backing for a new cystic fibrosis therapy, Alyftrek, that could be an option for 89% of NHS patients with the genetic disorder.

#cysticfibrosis #Vertex #NHSuse #VertexPharma #NHS #England #Wales #CFpatients #Reimbursement #NICE #NICEapproved #NICEguidance #Alyftrek #deutivacaftor #tezacaftor #vanzacaftor #F508delmutation #CFTRgene #cysticfibrosispatients #SKYLINE102 #SKYLINE103
pharmaphorum.com/news/new-cys...